EXELIXIS INC (EXEL) Fundamental Analysis & Valuation

NASDAQ:EXEL • US30161Q1040

Current stock price

42.82 USD
+1.25 (+3.01%)
Last:

This EXEL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. EXEL Profitability Analysis

1.1 Basic Checks

  • EXEL had positive earnings in the past year.
  • EXEL had a positive operating cash flow in the past year.
  • Each year in the past 5 years EXEL has been profitable.
  • In the past 5 years EXEL always reported a positive cash flow from operatings.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

1.2 Ratios

  • With an excellent Return On Assets value of 27.51%, EXEL belongs to the best of the industry, outperforming 97.50% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 36.21%, EXEL belongs to the top of the industry, outperforming 97.69% of the companies in the same industry.
  • The Return On Invested Capital of EXEL (29.21%) is better than 99.04% of its industry peers.
  • EXEL had an Average Return On Invested Capital over the past 3 years of 18.74%. This is in line with the industry average of 18.95%.
  • The 3 year average ROIC (18.74%) for EXEL is below the current ROIC(29.21%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 27.51%
ROE 36.21%
ROIC 29.21%
ROA(3y)17.42%
ROA(5y)13.41%
ROE(3y)22.87%
ROE(5y)17.28%
ROIC(3y)18.74%
ROIC(5y)14.42%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

1.3 Margins

  • Looking at the Profit Margin, with a value of 33.73%, EXEL belongs to the top of the industry, outperforming 95.57% of the companies in the same industry.
  • In the last couple of years the Profit Margin of EXEL has grown nicely.
  • Looking at the Operating Margin, with a value of 38.48%, EXEL belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
  • EXEL's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 96.39%, EXEL belongs to the best of the industry, outperforming 95.95% of the companies in the same industry.
  • In the last couple of years the Gross Margin of EXEL has remained more or less at the same level.
Industry RankSector Rank
OM 38.48%
PM (TTM) 33.73%
GM 96.39%
OM growth 3Y45.44%
OM growth 5Y28.11%
PM growth 3Y43.92%
PM growth 5Y24.4%
GM growth 3Y0%
GM growth 5Y0.01%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. EXEL Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
  • EXEL has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, EXEL has less shares outstanding
  • There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • EXEL has an Altman-Z score of 11.73. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 11.73, EXEL belongs to the top of the industry, outperforming 84.01% of the companies in the same industry.
  • There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.73
ROIC/WACC3.15
WACC9.28%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.3 Liquidity

  • EXEL has a Current Ratio of 3.56. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.56, EXEL perfoms like the industry average, outperforming 42.20% of the companies in the same industry.
  • EXEL has a Quick Ratio of 3.50. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
  • EXEL has a Quick ratio of 3.50. This is comparable to the rest of the industry: EXEL outperforms 43.93% of its industry peers.
Industry RankSector Rank
Current Ratio 3.56
Quick Ratio 3.5
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. EXEL Growth Analysis

3.1 Past

  • EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.73%, which is quite impressive.
  • The Earnings Per Share has been growing by 51.25% on average over the past years. This is a very strong growth
  • Looking at the last year, EXEL shows a small growth in Revenue. The Revenue has grown by 6.98% in the last year.
  • The Revenue has been growing by 18.63% on average over the past years. This is quite good.
EPS 1Y (TTM)49.73%
EPS 3Y69.38%
EPS 5Y51.25%
EPS Q2Q%83.33%
Revenue 1Y (TTM)6.98%
Revenue growth 3Y12.93%
Revenue growth 5Y18.63%
Sales Q2Q%5.63%

3.2 Future

  • EXEL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.04% yearly.
  • Based on estimates for the next years, EXEL will show a small growth in Revenue. The Revenue will grow by 6.37% on average per year.
EPS Next Y13.25%
EPS Next 2Y17.4%
EPS Next 3Y20.79%
EPS Next 5Y10.04%
Revenue Next Year11.13%
Revenue Next 2Y12.25%
Revenue Next 3Y11.89%
Revenue Next 5Y6.37%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. EXEL Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.46 indicates a correct valuation of EXEL.
  • Compared to the rest of the industry, the Price/Earnings ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 95.18% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.50. EXEL is valued slightly cheaper when compared to this.
  • Based on the Price/Forward Earnings ratio of 13.65, the valuation of EXEL can be described as correct.
  • Based on the Price/Forward Earnings ratio, EXEL is valued cheaply inside the industry as 96.34% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.67, EXEL is valued a bit cheaper.
Industry RankSector Rank
PE 15.46
Fwd PE 13.65
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 95.95% of the companies in the same industry are more expensive than EXEL, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 97.30% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 12.7
EV/EBITDA 9.94
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • EXEL's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of EXEL may justify a higher PE ratio.
  • A more expensive valuation may be justified as EXEL's earnings are expected to grow with 20.79% in the coming years.
PEG (NY)1.17
PEG (5Y)0.3
EPS Next 2Y17.4%
EPS Next 3Y20.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EXEL Dividend Analysis

5.1 Amount

  • EXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EXEL Fundamentals: All Metrics, Ratios and Statistics

EXELIXIS INC

NASDAQ:EXEL (3/25/2026, 10:55:06 AM)

42.82

+1.25 (+3.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10
Earnings (Next)05-11
Inst Owners102.75%
Inst Owner Change1.5%
Ins Owners2.23%
Ins Owner Change-0.22%
Market Cap11.12B
Revenue(TTM)2.32B
Net Income(TTM)782.57M
Analysts74.81
Price Target48.11 (12.35%)
Short Float %10.39%
Short Ratio9.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.16%
Min EPS beat(2)7.04%
Max EPS beat(2)9.27%
EPS beat(4)4
Avg EPS beat(4)19.83%
Min EPS beat(4)7.04%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)29.32%
EPS beat(12)9
Avg EPS beat(12)15.98%
EPS beat(16)13
Avg EPS beat(16)18.75%
Revenue beat(2)0
Avg Revenue beat(2)-1.79%
Min Revenue beat(2)-2.85%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)0.68%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.27%
Revenue beat(12)4
Avg Revenue beat(12)2.32%
Revenue beat(16)6
Avg Revenue beat(16)1.65%
PT rev (1m)2.91%
PT rev (3m)4.81%
EPS NQ rev (1m)-1.78%
EPS NQ rev (3m)-6.02%
EPS NY rev (1m)-3.47%
EPS NY rev (3m)1.88%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-3.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.09%
Valuation
Industry RankSector Rank
PE 15.46
Fwd PE 13.65
P/S 4.79
P/FCF 12.7
P/OCF 12.58
P/B 5.15
P/tB 5.3
EV/EBITDA 9.94
EPS(TTM)2.77
EY6.47%
EPS(NY)3.14
Fwd EY7.33%
FCF(TTM)3.37
FCFY7.88%
OCF(TTM)3.4
OCFY7.95%
SpS8.93
BVpS8.32
TBVpS8.08
PEG (NY)1.17
PEG (5Y)0.3
Graham Number22.77
Profitability
Industry RankSector Rank
ROA 27.51%
ROE 36.21%
ROCE 36.6%
ROIC 29.21%
ROICexc 51.64%
ROICexgc 54.14%
OM 38.48%
PM (TTM) 33.73%
GM 96.39%
FCFM 37.75%
ROA(3y)17.42%
ROA(5y)13.41%
ROE(3y)22.87%
ROE(5y)17.28%
ROIC(3y)18.74%
ROIC(5y)14.42%
ROICexc(3y)32.95%
ROICexc(5y)27.65%
ROICexgc(3y)34.51%
ROICexgc(5y)29.16%
ROCE(3y)23.48%
ROCE(5y)18.07%
ROICexgc growth 3Y66.65%
ROICexgc growth 5Y32.48%
ROICexc growth 3Y66.54%
ROICexc growth 5Y33.67%
OM growth 3Y45.44%
OM growth 5Y28.11%
PM growth 3Y43.92%
PM growth 5Y24.4%
GM growth 3Y0%
GM growth 5Y0.01%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 29.01%
Cap/Sales 0.36%
Interest Coverage 250
Cash Conversion 95.93%
Profit Quality 111.92%
Current Ratio 3.56
Quick Ratio 3.5
Altman-Z 11.73
F-Score7
WACC9.28%
ROIC/WACC3.15
Cap/Depr(3y)95.03%
Cap/Depr(5y)177.94%
Cap/Sales(3y)1.3%
Cap/Sales(5y)2.02%
Profit Quality(3y)127.23%
Profit Quality(5y)142.21%
High Growth Momentum
Growth
EPS 1Y (TTM)49.73%
EPS 3Y69.38%
EPS 5Y51.25%
EPS Q2Q%83.33%
EPS Next Y13.25%
EPS Next 2Y17.4%
EPS Next 3Y20.79%
EPS Next 5Y10.04%
Revenue 1Y (TTM)6.98%
Revenue growth 3Y12.93%
Revenue growth 5Y18.63%
Sales Q2Q%5.63%
Revenue Next Year11.13%
Revenue Next 2Y12.25%
Revenue Next 3Y11.89%
Revenue Next 5Y6.37%
EBIT growth 1Y29.39%
EBIT growth 3Y64.24%
EBIT growth 5Y51.98%
EBIT Next Year22.31%
EBIT Next 3Y19.91%
EBIT Next 5Y-5.79%
FCF growth 1Y30.42%
FCF growth 3Y37.77%
FCF growth 5Y37.42%
OCF growth 1Y26.33%
OCF growth 3Y34.6%
OCF growth 5Y33.44%

EXELIXIS INC / EXEL Fundamental Analysis FAQ

What is the fundamental rating for EXEL stock?

ChartMill assigns a fundamental rating of 8 / 10 to EXEL.


Can you provide the valuation status for EXELIXIS INC?

ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.


Can you provide the profitability details for EXELIXIS INC?

EXELIXIS INC (EXEL) has a profitability rating of 9 / 10.


Can you provide the financial health for EXEL stock?

The financial health rating of EXELIXIS INC (EXEL) is 9 / 10.


What is the expected EPS growth for EXELIXIS INC (EXEL) stock?

The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 13.25% in the next year.